Stay updated with breaking news from 09057220. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) EVP Timothy S. Ernst sold 300 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $384.69, for a total value of $115,407.00. Following the completion of the transaction, the executive vice president now owns 2,416 […]
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) had its price objective decreased by equities researchers at Wells Fargo & Company from $550.00 to $525.00 in a research report issued on Monday, Marketbeat.com reports. The firm presently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s target price would suggest a […]
Bio-Rad Laboratories (NYSE:BIO – Free Report) had its target price reduced by Wells Fargo & Company from $550.00 to $525.00 in a research note released on Monday morning, Marketbeat.com reports. They currently have an overweight rating on the medical research company’s stock. A number of other analysts have also weighed in on BIO. Credit Suisse […]
Hosking Partners LLP lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 17.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 52,290 shares of the medical research company’s stock after selling 10,762 shares during the period. […]
Bio-Rad Laboratories (NYSE:BIO – Free Report) had its price objective raised by Royal Bank of Canada from $522.00 to $524.00 in a report published on Friday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the medical research company’s stock. A number of other research firms also recently commented on BIO. […]